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Abstract
S100A1, a member of the large EF-hand family of Ca2-binding proteins, is mainly expressed in the mammalian heart. To
assess the underlying mechanisms for cell- and tissue-specific expression we isolated and characterized the mouse S100A1
gene. The gene displays a high degree of homology to the human and rat genes, especially in the exonic sequences. In its
promoter region and the first intron, we identified regulatory elements characteristic for cardiac and slow skeletal muscle
restricted genes. Transfection assays with luciferase constructs containing different parts of the S100A1 gene demonstrated
the active expression in primary mouse cardiomyocytes and that its 5P-upstream region containing a putative cardiac
enhancer showed a greatly increased activity. Furthermore, we investigated the expression of the S100A1 mRNA during
embryonic mouse development, using in situ hybridization. S100A1 transcripts were first detected in the primitive heart at
embryonic day (E) 8, with equal levels in the atrium and ventricle. During development up to E17.5 we detected a shift in the
S100A1 expression pattern with lower levels in atrial and high levels in ventricular myocardium. The regulatory elements
identified in the mouse S100A1 promoter correspond well with the observed expression pattern and suggest that S100A1 has
an important function during heart muscle development. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
S100 proteins constitute a family of calcium-bind-
ing proteins that exhibit cell- and tissue-speci¢c ex-
pression. They are thought to mediate regulatory
calcium signals via speci¢c interaction with various
e¡ector proteins. The Ca2-dependent conformation-
al change responsible for interaction with these target
proteins exposes hydrophobic regions to the surface
of the protein [1^4]. Apart from calcium, some S100
proteins also bind other divalent cations such as
Zn2 and Cu2 [1], which might modify their calcium
response.
Most S100 genes are organized in a gene cluster
located on human chromosome 1q21 [5] or mouse
chromosome 3 [6], leading to the designation
S100A1 to S100A13. Interestingly, most S100 genes
are similarly organized in three exons and two in-
trons. During evolution the members of the S100
family are highly conserved between species both at
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the DNA (85^95%) and at the protein (90^99%) lev-
el. However, each family member exhibits a unique
cell- and tissue-speci¢c expression pattern and bio-
chemical characteristics.
S100A1 is highly expressed in heart muscle where
it colocalizes with the sarcoplasmic reticulum (SR)
and intercalated discs [7]. An important role is pro-
posed for S100A1 in heart based on its abundance
and interaction with a number of e¡ector proteins
such as kinases, cytoskeletal proteins, enzymes, tran-
scription factors, and annexins (reviewed in [3,8]).
Intriguingly, downregulation of S100A1 expression
was observed in human cardiomyopathies, suggesting
that S100A1 is closely associated with the patho-
physiology of cardiomyopathies [9].
Whereas a large number of in vitro studies have
been carried out to investigate the function of S100
proteins, only a few developmental data are available
to date [10^13]. Hence, our aim was to analyze the
expression of S100A1 during di¡erent stages of
mouse development by in situ hybridizations. To be-
gin to assess the underlying genetic regulation we
determined the sequences of the mouse S100A1
gene and its 5P-£anking region and compared them
to known S100 gene sequences and various genes
expressed in a cardiac-speci¢c manner. In addition,
we performed activity studies with di¡erent frag-
ments of the S100A1 gene to demonstrate the func-
tionality of the isolated gene in primary mouse car-
diomyocytes.
2. Materials and methods
2.1. Cloning of the S100A1 gene
The sequence of the mouse cDNA coding for
S100A1 was derived from a sequence comparison
of EST databases with the human S100A1 cDNA
sequence (EST clone AC: AA109939) [6].
Primers used in the PCR reactions were derived
from the cDNA sequence using the OLIGO program
(Version 4.0). PCR reactions were performed with
mouse genomic DNA (Promega, Madison, WI,
USA) as template using the Expand High Fidelity
PCR System (Roche Diagnostics, Rotkreuz, Switzer-
land). Cycling was done in a GeneAmp PCR System
9700 (Perkin Elmer Applied Biosystems, Norwalk,
CT, USA) with the following parameters: intron I
PCR: 95‡C for 5 min, followed by 30 cycles at
95‡C, 10 s; 55‡C, 30 s; 68‡C, 3 min; and 68‡C for
7 min; intron II PCR: 95‡C for 5 min, followed by
30 cycles at 95‡C, 10 s; 55‡C, 30 s; 68‡C, 3 min; and
68‡C for 7 min.
Fragments of interest were gel-puri¢ed using the
QIAquick Gel Extraction Kit (Qiagen, Basel, Swit-
zerland) and subcloned directly into the pCR-TOPO
vector using the TOPO TA Cloning Kit (Invitrogen,
Groningen, The Netherlands). Further subcloning
was done with appropriate restriction endonucleases
(Life Technologies, Basel, Switzerland) and T4 Li-
gase (Life Technologies) into pUC18 (MBI Fermen-
tas, Amherst, NY, USA). DNA was puri¢ed using
the QIAprep Miniprep Kit (Qiagen, Rotkreuz, Swit-
zerland). Sequencing of the subcloned fragments was
performed by the Sanger dideoxy method. Sequenc-
ing primers were derived from known sequences
(primer walking) or standard primers (FORWARD/
REVERSE) were used. Sequencing reactions were
done with the BigDye Terminator Cycle Sequencing
Kit (PE Biosystems, Rotkreuz, Switzerland) follow-
ing the manufacturer’s procedures. Sequences were
determined using an ABI Prism 310 Genetic Ana-
lyzer (PE Applied Biosystems, Rotkreuz, Switzer-
land).
Determination of 5P-£anking sequences of the
mouse S100A1 gene was done with the Mouse Ge-
nomeWalker Kit (Clontech, Palo Alto, CA, USA).
Standard protocols of the supplier were used. Nested
PCR products were cloned into the pCR-TOPO vec-
tor and sequenced as described above.
2.2. Sequence analysis
Sequence assembly and analysis was done with the
Wisconsin Package Version 9.1 (Genetics Computer
Group (GCG), Madison, WI, USA).
Searching for potential transcription factor bind-
ing sites and regulatory sequences was performed
with the MatInspector [14] and AliBaba2 program
[15] with TRANSFAC 3.5 matrices [16]. Additional
consensus sequences for cardiac and slow skeletal
muscle-speci¢c transcription factors were taken
from [17]. Sequence comparisons were performed
with GAP of the GCG program package using stan-
dard parameters. Furthermore, the arrangement of
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the putative binding sites was compared to the liter-
ature for cardiac and slow skeletal muscle-restricted
genes (e.g. [17,18]).
The S100A1 sequences used have the following
accession numbers: U26356 (rat promoter, exon I,
and fragment of intron I), U26357 (fragments of
rat introns I and II, and exon II), U26358 (fragment
of rat intron II, and exon III); X58079 (human
cDNA), AA109939 (mouse cDNA), M65210 (human
promoter fragment), AF218353 (S100A1 mouse).
The sequence for the bovine cDNA was taken from
[19]. The S100A1 protein sequences have the acces-
sion numbers P35467 (rat), P56565 (mouse), P02639
(bovine), and P23297 (human).
2.3. Oligonucleotides
For the ampli¢cation of intron I and intron II
of the S100A1 gene the following primers were
used: EX1UP: 5P-AGAACCTGCTCCGAAGTC-
AG-3P ; EX2LOW: 5P-GCATGGAACACATTGAT-
GAG-3P ; EX2UP: 5P-GCACAGGAAGGGGACA-
AATA-3P ; EX3LOW: 5P-CCACCAGCACAACAT-
ACTCC-3P.
For the primer extension assay the following prim-
er was used: PRIMEX: 5P-CTCCATGGCACTCTC-
CAGCTCAGAG-3P.
Oligo for primer extension standard: pGEM-
FOR: 5P-GTCATAGCTGTTTCCTG-3P.
The following gene-speci¢c primers were used for
determination of 5P-£anking sequences with the
Mouse GenomeWalker Kit: GSP1: 5P-TGTAGG-
AAGACCTGGTAGCCTGGA-3P ; GSP2: 5P-CAG-
TATCCTTTTCCAGGGCTCTTGG-3P ; GSP3: 5P-
TCCCTTTCTTCCAGGCTGGCTAAGC-3P ; GSP4:
5P-TGAGACCCTGTGGTCCTTCCCTGAT-3P ;
GSP5: 5P-CCTTTGGGTCTCTTTGCCTTCTCAG-
3P.
The PCR products were gel-puri¢ed, subcloned,
and sequenced as described in the PCR section (see
above).
The following standard primers were used to de-
termine the sequences of fragments cloned into
pUC18 or pCR-TOPO: FORWARD: 5P-GTTTTC-
CCAGTCACGACGTTGTA-3P ; REVERSE: 5P-TT-
GTGAGCGGATAACAATTT-3P.
All oligonucleotides with the exception of standard
primers were derived from known sequences.
Oligonucleotides used for cloning of luciferase
constructs with S100A1 gene fragments were:
KON1: 5P-CATGGTACCTGAGGGCTCTTGGG-
AGTCTG-3P ; KON2: 5P-CAACCCGGGTCGACA-
GAAGGGCACGCTGC-3P ; KON3: 5P-ATCGGT-
ACCGGTGCAAGCAAGAACGGAAA-3P ; KON4:
5P-AGTCCCGGGTCAGCAGCACACCTACCC-
AT-3P ; KON5: 5P-TATCCCGGGTTTCCGTTCT-
TGCTTGCACC-3P ; KON6: 5P-TCAGGTACCTG-
TGGCGGTGTGCACTGTCC-3P.
To sequence the constructs of the pGL3 vector
family the following two primers were used:
RVprimer3: 5P-CTAGCAAAATAGGCTGTCCC-
3P ; RVprimer4: 5P-GACGATAGTCATGCCCCG-
CG-3P.
2.4. Primer extension assay
Total RNA was extracted from mouse hearts by
the guanidinium/cesium chloride method [20]. For
the primer extension reaction the PRIMEX oligonu-
cleotide (sequence see above) was labeled with
[32P]dATP using 1 unit polynucleotide kinase at
room temperature for 1 h. Oligonucleotides were pu-
ri¢ed using gel ¢ltration columns (MicroSpin G-25,
Amersham Pharmacia Biotech, Zurich, Switzerland).
Subsequent reactions were carried out as described in
the Primer Extension System (Promega). Brie£y, 1 ng
of the primer was hybridized in 22 Wl hybridization
bu¡er (50 mM Tris-HCl, pH 7.5, 50 mM KCl, 10
mM MgCl2, 10 mM DTT, 1 mM of each dNTP, and
0.5 mM spermidine) to 50 Wg of total RNA at 80‡C
for 15 min and cooled slowly to 37‡C. Reverse tran-
scription was done in a total volume of 40 Wl in the
same bu¡er adding sodium pyrophosphate to a total
concentration of 20 mM. After 1 h at 42‡C reactions
were stopped by addition of application bu¡er, de-
natured at 80‡C for 10 min and directly applied to a
denaturing 6% polyacrylamide gel. After the run
the gel was dried and subjected to autoradiography.
To determine the exact length of the resulting frag-
ments pGEM-FOR sequencing primer with the
pGEMz3Zf(+) vector as template was used as stan-
dard. Primer extension reactions with Escherichia coli
DNA (negative control) as template yielded no frag-
ments.
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2.5. Luciferase constructs
The S100A1 gene was ampli¢ed from the 5P-up-
stream region up to the beginning of exon II (con-
struct B) with the primers KON1(3510) and
KON4(+2164). Fragments for additional constructs
were ampli¢ed using the following primer com-
binations: KON1(3510)/KON2(+42) (construct A),
KON3(3153)/KON2(+42) (construct C), KON3-
(3153)/KON4(+2164) (construct D), or KON1-
(3510)/KON5(3152) (construct E). PCR reactions
were performed as described in Section 2.1, with
the following parameters: constructs B and D:
95‡C for 3 min, followed by 30 cycles at 95‡C, 10
s; 56‡C, 30 s; 72‡C, 2 min; and 72‡C for 7 min;
constructs A, C, and E: 95‡C for 3 min, followed
by 30 cycles at 95‡C, 10 s; 56‡C, 30 s; 72‡C, 45 s;
and 72‡C for 7 min.
Amplicons were gel-puri¢ed, digested with KpnI
and SmaI, then ligated into the pGL3 basic (con-
structs A^D) or pGL3 promoter (construct E) vec-
tors (all from Promega). The constructs were then
partially sequenced using the sequencing primers
RVprimer3 and RVprimer4 to ensure appropriate
insertion.
2.6. Cell culture and transfection assays
Neonatal mouse hearts were washed in PBS and
cut into small pieces. The extracellular matrix was
digested using Collagenase/Dispase (Roche Diagnos-
tics, Rotkreuz, Switzerland), the cells suspended in
DMEM, and then plated onto 35 mm dishes. After
48 h the cells were transfected by the CaPO4 method
[20] with 5 Wg of the pGL3 vector constructs and 1 Wg
of the pRSV-LGal vector (Promega) to assess the
transfection e⁄ciency.
Activities of all constructs were determined with
the Luciferase Assay System (Promega) 48 h after
transfection. For luciferase activity determinations
10 Wl of cell lysates were mixed with 50 Wl luciferase
assay reagent (Promega) and immediately measured
in a liquid scintillation analyzer (Packard 1900CA)
for 30 s. For L-galactosidase activity measurements
100 Wl 2U assay bu¡er (120 mM Na2HPO4, 80 mM
NaH2PO4, 2 mM MgCl2, 100 mM L-mercaptoetha-
nol, 1.33 mg/ml o-nitrophenyl-L-galactopyranoside
(N-1127, Sigma, Buchs, Switzerland)) was added to
100 Wl of cell lysate. The mixture was then vortexed
and incubated at 37‡C until a faint yellow color de-
veloped. Reactions were stopped by adding 330 Wl of
1 M sodium acetate and extinction was measured at
420 nm. Luciferase activities were normalized by L-
galactosidase activities. Results are based on at least
four experiments.
2.7. Preparation of S100A1 probe
The insert (S100A1 cDNA) of EST clone
AA110939 was cut out from the pT3T7 vector using
restriction enzymes NotI and EcoRI. The fragment
was gel-puri¢ed and labeled with [32P]dATP follow-
ing the manufacturer’s protocol (Prime-a-gene,
Promega) and ¢nally puri¢ed using gel ¢ltration col-
umns (MicroSpin S-300 HR, Amersham Pharmacia
Biotech).
2.8. Southern blot analysis
Mouse genomic DNA was digested with the ap-
propriate restriction enzymes for 6 h and separated
overnight in a 1% agarose gel. After blotting to Ny-
tran Nylon membrane (SchleicherpSchuell, Dassel,
Germany) ¢lters were hybridized with the
[32P]dATP-labeled probe speci¢c to exon II of the
S100A1 sequence, washed and exposed as described
elsewhere [6].
2.9. Northern blot analysis
Total RNA was extracted from di¡erent mouse
tissues by the guanidinium/cesium chloride method
[20]. Per lane 5 Wg were loaded, separated in a 1%
agarose-formaldehyde gel and blotted onto a nitro-
cellulose membrane. Additionally, a mouse RNA
Master Blot (Clontech) with spots of mRNAs from
di¡erent mouse tissues normalized for housekeeping
genes was used. Blots were hybridized with a radio-
labeled cDNA probe speci¢c for S100A1 or L-actin.
2.10. In situ hybridization
Preparation of embryonal sections and the condi-
tions used for hybridization procedures are described
elsewhere [21]. The mouse S100A1 cDNA was used
as 35S-labeled riboprobe both in antisense and sense
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direction (as control). The investigation conforms
with the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of
Health (NIH Publication No. 85-23, revised 1996).
3. Results
3.1. Structure of the mouse S100A1 gene
To analyze the structure and sequence of the
mouse S100A1 gene we ¢rst ampli¢ed intron I
(2058 bp) and intron II (631 bp) fragments with
mouse genomic DNA as template, using the two
primer pairs EX1UP/EX2LOW and EX2UP/EX3-
LOW located in the three putative exons of the
S100A1 mouse gene. PCR fragments were subcloned,
and sequenced using primer walking techniques.
Comparison of the exon-intron structure of the
mouse S100A1 gene to di¡erent species (Fig. 1) re-
vealed that the general organization of the gene
(three exons^two introns) as well as the length of
intron I (approx. 2 kb) are very well conserved.
However, the size of intron II varies from approx.
0.6 kb in mouse, through approx. 0.8 kb in human,
to approx. 3 kb in rat. Exon I (94 bp) codes for 5P-
untranslated sequences, while exon II (156 bp) con-
tains 5P-untranslated sequences and the N-terminal
S100-speci¢c EF-hand. The C-terminal ‘classical’
EF-hand of S100A1 and the 3P-untranslated sequen-
ces are located in exon III (197 bp). This is in agree-
ment with the general scheme of the S100 genomic
structure. In exon-intron border sequences, the clas-
sical splicing-donor and -acceptor motifs (GT- -AG)
are always present.
Next, to isolate 5P-£anking sequences, nested PCR
reactions were performed with S100A1 gene-speci¢c
primers and adapter primers linked to genomic libra-
ries used as templates. Using this technique, 525 bp
of the 5P-£anking sequence could be isolated. To de-
termine the transcription start site of the S100A1
mRNA, we performed a primer extension assay.
The reaction resulted in a main fragment of approx.
143 bp and a smaller fragment of approx. 120 bp
(Fig. 4), which allowed to assign the transcription
start site of the S100A1 gene to the ¢rst nucleotide
of the EST-derived cDNA [22].
Further sequence comparisons of S100A1 genes
(complete sequences and coding parts), intron frag-
Table 1
Comparison of S100A1 mouse sequences with other species
Compared
species
cDNA
(%)
Coding cDNA
(%)
Protein
(%)
Mouse-rat 91 88 94
Mouse-human 81 87 93
Mouse-bovine 76 94 94
Human-rat 82 88 97
Rat-bovine 77 90 98
Human-bovine 88 94 99
Compared
species
Intron I
(%)
Intron II
(%)
Promoter
(%)
Mouse-rat 79a 54a 81a
Mouse-human 56a
Human-rat 50a
Comparisons were performed with the GAP program included
in the GCG program package, with standard parameters. Ac-
cession numbers of the sequences are listed in Section 2.
aDue to limited sequence information, comparisons are based
on available sequence fragments. Intron I and intron II values
are expressed as mean values of two fragments located at the
intron-exon borders of the rat sequence.
Fig. 1. Comparison of the structural organization of the mouse S100A1 gene with S100A1 genes from di¡erent species. Boxes indicate
exonic sequences, shaded boxes are coding parts of the exons, and unshaded parts of exon I contain untranslated sequences. Length
of the ¢rst intron is well conserved between mouse, human, and rat sequences, whereas intron II varies in length among species.
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ments and promoter sequences between the S100A1
mouse, human, and rat gene are shown in Table 1.
The homology of S100A1 cDNAs ranges from 76%
(mouse-bovine) to 91% (mouse-rat). As expected,
even higher values of homology were found for the
coding regions only (87% for mouse-human or 94%
for mouse-bovine and human-bovine). Comparing
the coding region of the mouse-rat cDNAs, a slightly
lower homology (88%) was found than for complete
S100A1 cDNA sequences (91%). In intronic parts of
the mouse and rat genes, sequence homology was
generally lower than in exonic parts, with a striking
di¡erence between intron I (79% homology) and in-
tron II (54% homology). Promoter sequences were
compared between mouse, rat, and human with the
homology being signi¢cantly higher between rodent
species than between human and rodent (mouse-hu-
man, 56%; and human-rat, 50%). Comparisons are
based on the length of the human promoter fragment
(approx. 400 bp). The homology based on the rodent
promoter sequence (approx. 1 kb) was found to be
slightly higher (81%).
To exclude any possible rearrangements, the struc-
ture of the S100A1 gene was con¢rmed by Southern
blot analysis (Fig. 3; probe shown in Fig. 2). Restric-
tion of mouse genomic DNA with EcoRI, SmaI or
NheI resulted in fragments of approx. 3.5 kb, ap-
prox. 7 kb or approx. 8 kb (see arrows Fig. 3), re-
spectively. The SmaI and NheI fragments contain the
entire S100A1 gene, whereas EcoRI cuts in the ¢rst
intron and covers exon II, exon III and the 3P-down-
stream region. In summary, comparison of the ge-
nomic structure of the mouse S100A1 gene with oth-
er species reveals conservation of the general
structure, with some di¡erences seen in 5P-£anking
and intronic regions.
3.2. Analysis of putative regulatory sequences
To identify putative regulatory motifs within the
Fig. 2. Mouse S100A1 gene structure and location of putative transcription factor binding sites. Plain and shaded boxes indicate un-
translated and translated exonic sequences, respectively. Normal line signi¢es promoter or intronic sequences. The basal promoter
used in transfection studies and the putative cardiac muscle enhancer are shown in brackets. Restriction sites are marked by arrows
and enzymes are abbreviated (E, EcoRI; H, HindIII; Pv, PvuII; B, BamHI; Bg, BglII; S, SmaI; N, NheI). mCEF, mouse cardiac en-
hancer factor; CPF, cardiac promoter factor; MEF, myocyte enhancer factor; CRE, cAMP responsive element. The bar below exon
II indicates the position of the Southern blot probe (SBP) used for hybridization.
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S100A1 promoter region, sequences were screened by
computer analysis for possible transcription factor
binding sites that might control transcriptional activ-
ity of the gene using TRANSFAC 3.5 matrices [16].
Several potential transcriptional regulatory sites have
been identi¢ed, some of which are illustrated in Fig.
2. Selections were based on best score for the con-
sensus motifs and potential regulatory function in
skeletal and cardiac muscle. We failed to identify
items that commonly specify the transcription start
such as CAAT box, TATA box or initiator-speci¢c
sequences [23] 20^30 bp upstream from the cDNA
start site. The 5P-£anking region contains putative
consensus motifs for general basal transcription fac-
tors, including AP2 (375 [24]), M-CAT (3113, 379
[24]), C/EBPK (3445 [24]), Oct-1 (3453 [24]), and
SP1 (3119 [25]). In addition, muscle-speci¢c tran-
scription factor motifs were found in the promoter
region, i.e. mCEF-1 (3172), CEF-2 (343, 324),
CPF-1 (362), CPF-3 (+88), and MEF-3 (+106),
which are known to be involved in cardiac-speci¢c
gene expression [17]. Furthermore, a single consensus
sequence for glucocorticoid receptor binding (3441
[24]) was found. Sequences in intron I contained sev-
eral enhancer motifs well known to be present in
cardiac restricted genes such as cardiac troponin C
and cardiac actin. These motifs bind transcription
factors with known regulatory functions in develop-
ment, i.e. Nkx-2.5 (+888 [26]), MEF-2 (+683 [27]),
MEF-3 (+919 [17]), and MyoD (+974 [28]) as well as
several cAMP-responsive element (CRE) motifs
(+76, +510, +517 [29]) known to be responsible for
cyclic AMP and Ca2-dependent gene expression in
di¡erentiated tissues. A putative SURE region re-
sponsible for expression of troponin I in slow skeletal
muscle was found, including binding sites for MEF-
2, a CACC motif, a CAGG motif, an MEF-3 site,
and an E box [18].
A (GCT)4 trinucleotide repeat, with the second
repeat being ACT, was found at position 3478 in
the promoter.
Fig. 4. Primer extension assay. (A) Primer extension was per-
formed with total mouse cardiac RNA. Lanes A, C, G, T: se-
quencing of pGEMz3Zf(+) vector with the pGEM-FOR se-
quencing primer as size standard. Lane descriptions depict
didesoxynucleotide added to the cycle sequencing reactions.
Primer extension reaction is shown in lane P with two frag-
ments of 120 and 143 bp (see arrows). (B) Transcription start
sites in the S100A1 sequence. The two fragments shown in pan-
el A indicate two transcriptional start sites located at positions
+1 and +23 as depicted in the sequence.
Fig. 3. Southern blot analysis of mouse genomic DNA using
di¡erent restriction endonucleases. DNA was digested with
EcoRI, SmaI, and NheI, separated on a 1% agarose gel, blotted
and hybridized with an [32P]dATP-labeled cDNA probe speci¢c
for exon II of the mouse S100A1 gene (SBP; see Fig. 2). Ar-
rows indicate the length of the di¡erent labeled fragments.
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Hence, regulation of S100A1 might involve vari-
ous known transcription factors.
3.3. Activity of S100A1 promoter in primary
cardiomyocytes
To functionally test the importance of various po-
tential transcription factor binding sites for expres-
sion of S100A1 in the mouse heart transfection ex-
periments were performed in primary mouse
cardiomyocytes with di¡erent fragments of the
S100A1 mouse gene sequence linked to a luciferase
reporter gene (Fig. 5). As controls, vectors alone or
containing an SV40 promoter and/or SV40 enhancer
were included. Transfection constructs are shown in
Fig. 5A. Activities of constructs A and B (Fig. 5B)
containing the 5P-upstream region of the S100A1
gene together with the basal promoter gene were
6.3 þ 1.4-fold (construct A) or 5.1 þ 1.5-fold (con-
struct B) higher than constructs C and D lacking
this region. Hence, the presence of intron I in con-
struct B has little or no in£uence on the expression of
the S100A1 gene in primary cardiomyocytes. The
S100A1 basal promoter (construct C) showed similar
activity levels as the non-heart speci¢c heterologous
promoter (pGL3 promoter). Testing the 5P-upstream
region on a heterologous SV40 promoter, a 5.3 þ 1.9-
fold (E) activation over basal levels was observed.
These experiments suggest that the 5P-upstream re-
gion of S100A1 contains an enhancer element that is
able to drive cardiomyocyte-speci¢c expression, even
on a heterologous promoter.
Transfections of constructs B, D, and E in NIH
3T3 mouse ¢broblasts showed no enhancing activity
of the 5P-upstream region of the S100A1 gene, thus
con¢rming its cardiac speci¢city.
Fig. 5. Luciferase constructs of the S100A1 mouse gene and transfection activities. (A) Structure of 5P-region of the S100A1 gene and
di¡erent promoter constructs for transfection assays; S100A1: structure of 5P-region of the S100A1 mouse gene; +1 indicates tran-
scription start site of full length cDNA and Roman ciphers designate the two exons of the gene. Constructs A^E: numbers describe
the position in the S100A1 sequence. Gene fragments were fused to a luciferase reporter gene to assay relative transcriptional activity.
(B) Relative luciferase activity of the di¡erent constructs depicted in panel A normalized with L-galactosidase activity transfected into
cardiomyocytes. pGL3 basic vector or pGL3 promoter vector was used for the production of constructs A^D or E, respectively. Fur-
thermore, constructs B, D, E and vectors alone were transfected into NIH 3T3 cells to ensure cardiac-speci¢c enhancement activity.
The pGL3 promoter vector (containing the SV40 promoter), the pGL3 control vector (additional SV40 enhancer), and the pGL3 basic
vector were transfected as controls into both cell types.
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3.4. Early expression of S100A1 during mouse heart
development
To study expression of S100A1 during mouse em-
bryonic development, [35S]labeled gene-speci¢c ri-
boprobes were hybridized to sections of mouse em-
bryos from embryonic day 8 (E8) to E17.5. S100A1
gene transcripts were ¢rst detected at a low level in
the primitive myocardium at E8.0 (Fig. 6A). Expres-
sion of S100A1 was much higher in extraembryonic
yolk sac and maternal decidual tissues. Subsequent
developmental stages were dissected away from ma-
ternal and extraembryonic tissues prior to sectioning.
At E9.0, S100A1 mRNAs were detected in the loop-
ing heart in both the common atrium and common
ventricle (Fig. 6B). At E10.5 (Fig. 6C) and E11.5
(Fig. 6D), S100A1 gene transcripts occurred at equal
levels in the atrium and ventricle, including the walls
of the heart, trabeculations, and developing septa. At
E12.5^E13.5 (Fig. 6E,F), no signal for S100A1 was
detected over the endocardial cushion tissue and de-
veloping valves. As the compact layer of ventricular
myocardium formed from E13.5 to E17.5 (Fig. 6F^
K), S100A1 expression continued in both the com-
pact and trabecular layers. S100A1 mRNAs were
detected in atrial myocytes but at a lower level
Fig. 6. S100A1 expression in embryonic and fetal hearts by in situ hybridization using a speci¢c S100A1 sense/antisense mouse probe.
In a sagittal section of an 8 day embryo (A), S100A1 mRNAs were detected at a low level in heart (h). Expression levels were very
high in yolk sac (ys) and maternal decidual (d) cells. hf, headfold. At E9.5 (B, sagittal section), S100A1 gene transcripts were detected
in myocytes of the common atrium (a) and common ventricle (v). ba, branchial arch; nt, neural tube; s, somite. At E10.5 (C, frontal
section), S100A1 is expressed at equal levels in atrial (a) and ventricular (v) myocardium. In a transverse section of an E11.5 embryo
(D), S100A1 expression was evident in developing trabeculae (t) of the ventricle (v). At E12.5 (E, sagittal section), S100A1 expression
was not detected in the endocardial cushions (ecc) but was present in atrial (a) and ventricular (v) myocardium. At E13.5 (F, sagittal
section), S100A1 was detected in the compact layer (c) of the ventricle, was reduced in the atrial (a) myocardium, and was not de-
tected in the atrioventricular valves (av). At E14.5 (G, frontal section) S100A1 was detected in the muscular portion of the ventricular
septum (vs). H is a section serial to that in G hybridized to the sense control S100A1 probe to show the background level of silver
grains. At E15.5 (I, sagittal section), S100A1 mRNAs were present in the myocytes of the atrium (a) and ventricle, but not in the
non-muscle cells of the atrioventricular valve (av) or in smooth muscle of the aorta (ao). r, ribs. At E16.5 (J, sagittal section), S100A1
gene transcripts were not detected in lung tissue (lu). At E17.5 (K, transverse section), S100A1 mRNAs were expressed at high level
in the compact (c) and trabecular (t) layers of the ventricular (v) myocardium, at low level in the atrial (a) myocardium, but were not
detected in the aorta (ao) or the pulmonary artery (pa). Scale bar in C = 100 Wm for A^H. Scale bar in J = 50 Wm for I^K. All panels
are dark¢eld micrographs.
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than in ventricular myocardium (Fig. 6F^K).
S100A1 expression was not detected in the aorta
(Fig. 6I,K), in the pulmonary artery (Fig. 6K), in
the sinus venosus (data not shown), in the caval my-
ocardium (Fig. 6E), in myocardium surrounding
blood vessels entering the lungs (Fig. 6J), or in nodal
tissue (data not shown). A sense control probe was
hybridized to a serial section for each antisense
probe. One of the sense control results for E14.5
(Fig. 6G, antisense) is shown in Fig. 6H to show
the background level of silver grains for these experi-
ments. After E16.5, S100A1 mRNAs were also de-
tected in brown fat developing in the upper back of
the embryo (data not shown).
3.5. Expression of S100A1 in di¡erent mouse tissues
We analyzed the adult expression pattern of
Fig. 7. Northern blot analysis of di¡erent adult mouse tissues. Total mouse RNAs of the described tissues were separated, blotted,
and hybridized to a labeled S100A1-speci¢c probe (A). Additionally, we performed a dot blot analysis with mouse mRNAs from dif-
ferent tissues (B). Tissues are shown in panel C; rows A^D: mRNAs from adult tissues, row E: mRNAs from total embryos. A spe-
ci¢c probe for L-actin as a loading control (not shown for dot blot) was included.
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S100A1 by hybridizing a mouse tissue Northern blot
(Fig. 7A) and demonstrated that the S100A1 probe
used is speci¢c, since only one band could be de-
tected. Then we performed a Northern dot blot anal-
ysis with mRNA isolated from a range of di¡erent
mouse tissues (Fig. 7B,C). The strongest signals were
detected in adult heart and submaxillary gland, and
lower expression levels in adult skeletal muscle, kid-
ney, lung, thyroid gland, and brain. During embry-
onal development high levels of S100A1 expression
were found already at day 7 with expression decreas-
ing until day 17 (Fig. 7B).
As a result, the cardiac-restricted expression pat-
tern of S100A1 found very early in mouse develop-
ment is maintained in the adult animal, with addi-
tional expression observed in other tissues.
4. Discussion
In the present study we characterized the mouse
S100A1 gene and its putative transcriptional regula-
tors with the aim to investigate the mechanisms
underlying the cell- and tissue-speci¢c expression of
S100A1 in mouse heart.
The structural organization of S100 genes is highly
conserved. In general they are composed of three
exons and two introns, a structure also present in
the S100A1 mouse sequence. The length of the exons
was similar with some di¡erences found in exon III
(mouse, 197 bp; rat, 296 bp; and human, 354 bp). As
expected, high homology between the three coding
sequences results in a strong conservation of the
two EF-hands as functional units of the S100A1 pro-
tein. Comparing the intron lengths of the mouse and
rat sequences, we found a well conserved size for
intron I, while intron II varied signi¢cantly. Since
only a few regulatory motifs were identi¢ed in the
second intron, the divergent intron sizes of mouse
and rat might be due to less evolutionary pressure
to conservation.
Mapping of the transcription start site using a
primer extension assay con¢rmed that the EST
cDNA is a full length clone. A smaller fragment in-
dicates that multiple transcription start sites might be
used, as is characteristic for TATA-less GC-rich pro-
moters [30]. Indeed, the mouse S100A1 gene is GC-
rich (63% GC) in the promoter region as well as in
exon I (58% GC), and no consensus TATA boxes or
initiator elements were present.
Comparing potential regulatory sequences in the
promoter and intron I of mouse, rat, and human,
some interesting observations were made. A GCT
repeat in the mouse promoter is only poorly con-
served; however, SPE, CEF-1, and CEF-2 sites, the
M-CAT element, and the SP1 elements are conserved
in rat, mouse, and human. Several cAMP responsive
elements (CRE) were found in the mouse S100A1
gene, indicating a putative role for Ca2 and hormo-
nal signal transduction pathways (cAMP) in the reg-
ulation of S100A1. Therefore, the observed downre-
gulation of S100A1 during cardiomyopathies [9]
might be explained by the action of hypertrophic
stimuli or mechanical stress, transmitted via multiple
pathways in cardiomyocytes [31].
Since S100A1 is predominantly expressed in the
developing and adult heart, we searched for enhancer
sequences known from cardiac-restricted genes. It is
well known that cardiac gene expression is controlled
by the synergistic interaction of members of di¡erent
transcription factor families including homeobox-
containing Nkx factors, Zn2 ¢nger containing
GATA factors, and MADS box containing MEF
and SRF factors [32]. Thus, e.g. a cardiac enhancer
element (containing CEF-1, CEF-2, CPF-1, and
CPF-2 sites) controls the expression of the troponin
C gene in myocardium [17]. Additionally, the cardiac
troponin C gene is controlled by GATA-4, a tran-
scription factor important in the regulation of car-
diac development in mammals [33].
In the S100A1 gene we detected a putative regu-
latory motif, located in the 5P-£anking sequences,
with strong homologies to the cardiac enhancer ele-
ment from the troponin C gene, correlating well with
the observed expression pattern of the S100A1 gene.
Brie£y, homologies to a mouse-speci¢c CEF-1 site,
two CEF-2 sites, and sites for CPF-1 and CPF-3
were found to be located around the basal promoter
(see Fig. 2).
We demonstrated that the 5P-upstream region of
the S100A1 gene containing the putative cardiac en-
hancer is able to boost the transcriptional activity of
the S100A1 gene 6.3 þ 1.4-fold in primary mouse car-
diomyocytes, thus highlighting the importance of this
enhancer in cardiac expression of S100A1. The basal
promoter (construct C) of the S100A1 gene showed
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the same activity level as the heterologous SV40 pro-
moter (pGL3 promoter), indicating that additional
cardiac-speci¢c enhancer elements in the S100A1 se-
quence are responsible for the cardiac expression of
the S100A1 gene.
On the other hand, the presence or absence of
intron I sequences containing additional putative
transcription factor binding sites for the murine ho-
meobox gene Nkx-2.5 [28], MyoD, SRE, and a re-
gion showing strong homologies to the so-called
SURE region, did not in£uence transcriptional activ-
ity in primary mouse cardiomyocytes. As the tran-
scription factor Nkx-2.5 is known to be implicated in
the coordination of myogenic and morphological de-
velopment of the early heart tube [34] it could be
important in the developmental expression of
S100A1. The SURE region, a slow skeletal muscle
enhancer known from the troponin I and C genes,
contains putative binding sites for MEF-2, a CACC
motif, a CAGG motif, a MEF-3 site, and an E box
[18], and could be responsible for the known expres-
sion of the S100A1 gene in slow skeletal muscle.
Enhancer motifs found in several other S100 genes
may play a crucial role in determining their di¡er-
ential regulation during development and in adult
tissues, including S100A4, S100A8, S100A9, and
S100B. Hence, the genes located in the S100 cluster
appear to be regulated by individual enhancer ele-
ments. Furthermore, the homologies of the S100A1
gene to regulatory elements of the troponin family
point to a possible evolutionary relationship of gene
regulation as both protein families represent subfam-
ilies of the EF-hand Ca2-binding protein superfam-
ily.
The heart is the ¢rst organ to form during embry-
onic development, showing spontaneous contractions
as early as E8.0. Regular myocardial contractions of
the tubular heart are observed at E9^9.5 [35]. Using
in situ hybridization, S100A1 mRNAs were detected
above background at E8.0. S100A1 expression was
detected in the myocardium at all stages of embry-
onic and fetal development. Throughout this period,
S100A1-speci¢c hybridization signal increased in in-
tensity. The expression pattern changed from equal
levels in both atrium and ventricle to lower levels in
the atrial myocardium compared to ventricular my-
ocardium. Expression was not detected above back-
ground in non-muscle components of the heart such
as the endocardial cushions, valves, epicardium, and
endocardium.
Considering the subcellular location of the calci-
um-binding protein S100A1 in the sarcoplasmic re-
ticulum of cardiomyocytes, it is of much interest that
its early appearance in heart development has also
been shown for the sarcoplasmic reticulum Ca2-
ATPase (SERCA), its main regulator phospholam-
ban (PLB), gap junction proteins [36^38], and pro-
teins crucial for cardiac excitation-contraction (EC)
coupling [39]. Since dysfunction of Ca2 release and
reuptake in cardiomyocytes, resulting in intracellular
Ca2 overload, leads to cardiac arrhythmias and car-
diomyopathies [39,40], our results might suggest a
central role for S100A1 in the regulation of myocar-
dial contractility and pathogenesis of cardiomyopa-
thies, possibly in a concerted manner with proteins
involved in EC coupling.
Hence, the function of S100A1 is not limited to
developmental processes but continues in the adult
animal (Fig. 7A,B). This was con¢rmed by analyzing
S100A1 expression in adult mouse hearts by North-
ern and Western blotting (not shown) where S100A1
was detected in high amounts. Further studies of
S100A1 are underway to investigate the functional
importance of S100A1 in heart development, heart
function, and the pathogenesis of heart diseases.
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